ny (GenomeWeb) – Myriad Genetics introduced after the close of the market Tuesday the acquisition of Sividon Diagnostics in a deal that adds a breast cancer prognostic check to Myriad's product portfolio and enhances its competitive position in oncology diagnostics.
Myriad received Sividon for €35 million ($39 million) upfront and as much as €15 million in funds in keeping with the product reaching future performance milestones. The business funded the deal the usage of money handy.
0 komentar:
Posting Komentar